文献速递系统性红斑狼疮其他结缔组织病

Enpatoran(TLR7/8抑制剂)治疗皮肤型或系统性红斑狼疮皮肤表现的2期剂量探索研究

Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial.
PubMed 文献 · Lancet Rheumatol · 2026-05-07

WILLOW研究A队列为2期、随机、双盲、安慰剂对照、剂量探索试验,纳入102例活动性皮肤表现的皮肤型红斑狼疮或系统性红斑狼疮患者,随机接受安慰剂或Enpatoran 25/50/100 mg每日两次治疗24周。

要点

  • Enpatoran 25/50/100 mg每日两次在第16周显著剂量依赖性降低CLASI-A评分。
  • 最常见治疗中出现的不良事件为上呼吸道感染,各组发生率8%-19%。
  • 严重不良事件少见,安慰剂组1例、100 mg组1例、25 mg组2例,50 mg组无。

核心结论

  • Enpatoran对CLE或SLE活动性皮肤表现有显著且剂量依赖性的疾病活动度改善,且耐受性良好。

研究设计与样本

  • WILLOW为2期、随机、双盲、安慰剂对照、篮式、剂量探索研究,在22个国家132个中心开展。
  • A队列纳入18-75岁、仅CLE或SLE伴轻度或无皮肤黏膜外疾病活动(BILAG-2004评分1B、C或D)且CLASI-A评分≥8的参与者。
  • 参与者按1:1:1:1随机接受安慰剂或Enpatoran 25 mg、50 mg、100 mg每日两次治疗24周,联合标准治疗。
  • 主要目标为评估第16周CLASI-A总分较基线百分比变化的剂量反应关系,采用多重比较程序建模方法分析。
  • 疗效分析基于全分析集(100例),安全性分析基于至少接受一剂研究治疗的所有患者(102例)。

主要发现

  • 最常见治疗中出现的不良事件为上呼吸道感染,25 mg组2/24(8%)、50 mg组4/26(15%)、100 mg组5/26(19%)、安慰剂组2/26(8%)。
  • 严重不良事件:安慰剂组1/26(4%)、100 mg组1/26(4%)、25 mg组2/24(8%),50 mg组无报告。

关键数值与推荐

  • A队列入组标准包括CLASI-A评分≥8且BILAG-2004评分为1B、C或D。
  • 全分析集100例中位年龄47岁(IQR 36-55),女性77例(77%),男性23例(23%),白人48例(48%)。

临床怎么用

  • 对于以皮肤表现为主要活动性的CLE或SLE患者,Enpatoran每日两次25-100 mg可能作为联合标准治疗的选择,需进一步3期验证。

局限性

  • 研究未纳入有CLE或SLE亲身经历者参与设计。
  • A队列中2例随机分配后被判定不符合入选标准并排除于疗效分析。
  • B队列结果将另行报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Toll-like receptor (TLR)7 and TLR8 are nucleic-acid sensors involved in lupus pathogenesis. We aimed to investigate the efficacy and safety of enpatoran, an oral small-molecule TLR7/8 inhibitor, in participants with active skin manifestations of cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE). METHODS: WILLOW is a phase 2, randomised, double-blind, placebo-controlled, basket, dose-finding study conducted across 132 centres in 22 countries, enrolling patients into two cohorts (A and B) with different eligibility criteria. In Cohort A of the trial, we enrolled participants aged 18-75 years who had CLE only or SLE with mild or no extra-mucocutaneous disease activity (British Isles Lupus Assessment Group [BILAG]-2004 scores 1B, C, or D), and a Cutaneous Lupus Disease Area and Severity Index-activity (CLASI-A) score of 8 or higher. Participants were randomised (1:1:1:1) to receive placebo or enpatoran at a dose of 25 mg, 50 mg, or 100 mg twice per day for 24 weeks, in combination with standard of care. The primary objective was to evaluate the dose-response relationship of enpatoran in reducing disease activity, based on the percentage change from baseline in CLASI-A total score at week 16, analysed with a multiple comparison procedure-modelling approach. Efficacy analyses were done in the full analysis set of all randomly allocated participants. Safety was assessed in all patients who received at least one dose of study treatment. There was no involvement of people with lived experience of CLE or SLE in study design. This trial is registered with ClinicalTrials.gov (NCT05162586; completed); results from Cohort B will be reported separately. FINDINGS: Between May 4, 2022, and Feb 6, 2024, 463 patients were screened for eligibility across cohorts A and B; 102 participants were randomly assigned within Cohort A and received treatment (safety population). Two participants (n=1 each from the enpatoran 25 mg and 50 mg groups) were randomly allocated to Cohort A but were subsequently found to have had BILAG scores ≥1A and 2B at screening and were therefore deemed ineligible and excluded; thus 100 participants were analysed for efficacy (placebo group n=26; enpatoran 25 mg group n=23; enpatoran 50 mg group n=25; enpatoran 100 mg group n=26). Participants in the full analysis set had a median age of 47 years (IQR 36-55); 77 (77%) were female, 23 (23%) were male, and 48 (48%) were White. At week 16, enpatoran had a significant, dose-dependent effect on CLASI-A score, with adjusted mean changes from baseline of -64 percentage points (95% CI -70 to -58) in the enpatoran 25 mg group, -68 percentage points (-75 to -61) in the enpatoran 50 mg group, and -72 percentage points (-80 to -64) in the enpatoran 100 mg group, versus -44 percentage points (-55 to -33) in the placebo group (p=0·0002 for dose-response relationship). The most common treatment-emergent adverse event was upper respiratory tract infection, which occurred in two (8%) of 24 patients in the enpatoran 25 mg group, four (15%) of 26 in the enpatoran 50 mg group, five (19%) of 26 in the enpatoran 100 mg group, and two (8%) of 26 in the placebo group. Overall, one (4%) participant in the placebo group, one (4%) in the enpatoran 100 mg group, and two (8%) in the enpatoran 25 mg group had serious adverse events; none were reported with enpatoran 50 mg. INTERPRETATION: Enpatoran showed a significant and dose-dependent effect on disease activity in participants with active cutaneous manifestations of CLE or SLE, and was well tolerated. FUNDING: Merck Healthcare KGaA, Darmstadt, Germany.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Morand EF, Werth VP, Wenzel J, et al. Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Rheumatol. 2026. PMID: 42107375. doi:10.1016/S2665-9913(25)00337-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。